Outcomes at 2-Years Follow-Up After Hip Arthroscopy Combining Bone Marrow Concentrate

Rivera, Eila; Seijas, Roberto; Rubio, Mónica; García-Balletbó, Montserrat; Vilar, Jose M. G.; Boada, Patricia Laiz; Cugat, Ramón

doi:10.1080/08941939.2018.1535010

Cited by 11 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 One study investigated the use of liquid AMIC at two years’ follow-up. 62 One study used bone marrow concentrate (BMC), 63 and another used a chitosan-based scaffold. 53 A mixture of approaches was used to manage labral tears including repair, reconstruction, and debridement.…”

Section: Resultsmentioning

confidence: 99%

“…53 A mixture of approaches was used to manage labral tears including repair, reconstruction, and debridement. 19,27,36,51,54,58,63 Four studies only reported on labral debridement. 18,54,56,62…”

Section: Resultsmentioning

confidence: 99%

“…Two studies did not report rates of revision arthroscopy. 50,63 Nine studies reported the mean time to THA, with a pooled value of 39.1 months (3.0 to 99.2). 4,46-48,51,55,56,58,59 Eight studies, with a total of 784 patients, reported complications in 28 patients (3.57% complication rate).…”

Section: Resultsmentioning

confidence: 99%

“…Overall, there was a moderate risk of bias (Supplementary Figure h). Additional assessment of the study by Rivera et al, 63 which used BMCs, was performed using the MIBO tool (Supplementary Table ix). An overall score of 52.6% was obtained, with poor reporting of patients’ details, surgical intervention, and delivery of BMC.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Outcomes of arthroscopy of the hip for femoroacetabular impingement based on intraoperative assessment using the Outerbridge classification

Andronic

Zhang

et al. 2023

Bone Joint J

View full text Add to dashboard Cite

AimsHip arthroscopy (HA) has become the treatment of choice for femoroacetabular impingement (FAI). However, less favourable outcomes following arthroscopic surgery are expected in patients with severe chondral lesions. The aim of this study was to assess the outcomes of HA in patients with FAI and associated chondral lesions, classified according to the Outerbridge system.MethodsA systematic search was performed on four databases. Studies which involved HA as the primary management of FAI and reported on chondral lesions as classified according to the Outerbridge classification were included. The study was registered on PROSPERO. Demographic data, patient-reported outcome measures (PROMs), complications, and rates of conversion to total hip arthroplasty (THA) were collected.ResultsA total of 24 studies were included with a total of 3,198 patients (3,233 hips). Patients had significantly less improvement in PROMs if they had Outerbridge grade III and IV lesions (p = 0.012). Compared with microfracture, autologous matrix-induced chondrogenesis (AMIC) resulted in significantly reduced rates of conversion to THA (p = 0.042) and of revision arthroscopy (p = 0.038). Chondral repair procedures in these patients also did not significantly reduce the rates of conversion to THA (p = 0.931), or of revision arthroscopy (p = 0.218). However, compared with microfracture, AMIC significantly reduced the rates of conversion to THA (p = 0.001) and of revision arthroscopy (p = 0.011) in these patients. Those with Outerbridge grade III and IV lesions also had significantly increased rates of conversion to THA (p = 0.029) and of revision arthroscopy (p = 0.023) if they had associated lesions of the acetabulum and femoral head. Those who underwent labral debridement had a significantly increased rate of conversion to THA compared with those who underwent labral repair (p = 0.015).ConclusionThere is universal improvement in PROMs following HA in patients with FAI and associated chondral lesions. However, those with Outerbridge grade III and IV lesions had significantly less improvement in PROMs and a significantly increased rate of conversion to THA than those with Outerbridge grade I and II. This suggests that the outcome of HA in patients with FAI and severe articular cartilage damage may not be favourable.Cite this article: Bone Joint J 2023;105-B(7):751–759.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Outcomes of arthroscopy of the hip for femoroacetabular impingement based on intraoperative assessment using the Outerbridge classification

Andronic

Zhang

et al. 2023

Bone Joint J

View full text Add to dashboard Cite

show abstract

“…Rivera et al conducted a case control study comparing forty patients undergoing bone marrow concentrate combined with hip arthroscopic intervention to treat FAI as compared to forty patients undergoing arthroscopic intervention alone. [64] When compared to the control group, the BMC cohort demonstrated significant pain reduction at 12 and 24 months according to VAS and improvement in function at 12 and 24 months post-operative as measured by mHHS and iHOT-22 (0.033; 0.024). While this is a small study, it demonstrated potential for improved outcomes when MSCs are used as an adjunct to arthroscopy of the hip for the treatment of OA.…”

Section: Stem Cellsmentioning

confidence: 87%

The Use of Biologics for Hip Preservation

Jildeh

Abbas

Buckley

et al. 2021

Curr Rev Musculoskelet Med

View full text Add to dashboard Cite

Purpose of Review A wide array of nonoperative modalities to treat hip pain are aimed at restoring and maintaining the structural and physiologic characteristics of the joint. The purpose of this review is to describe the current understanding of biologics in hip pathology by providing an evidence-based overview of treatment modalities available for orthopedic surgeons. Recent Findings The use of biologics as a primary treatment or adjunct to traditional management has shown encouraging results for the treatment of hip pain. Studies have demonstrated safety with minimal complications when using platelet rich plasma, hyaluronic acid, or stem cells to treat hip pain caused by osteoarthritis, femoroacetabular impingement syndrome, tendinopathy, or osteonecrosis of the femoral head. Several studies have been able to demonstrate meaningful clinical results that can improve treatment standards for hip pain; however, more work must be performed to better delineate the appropriate protocols, indications, and limitations of each modality. Summary Recent advances have inspired renewed interest in biologics for patients with hip pain. We present a concise review of platelet rich plasma, hyaluronic acid, stem cells, and matrix metalloprotease inhibitors and their applicability to hip preservation surgery.

show abstract